Key result
Network pharmacology analysis identified 183 target genes and 24 pathways, including MDM2, TP53, and MAPK signaling, as key mechanisms for Yiqi Shexue formula in treating primary immune thrombocytopenia.
Why the study?
Yiqi Shexue formula is traditionally used to treat primary immune thrombocytopenia, but its mechanisms of action and molecular targets are not clear.
Network pharmacology analysis suggests that Yiqi Shexue formula may treat primary immune thrombocytopenia by regulating immunological function through specific biological processes and pathways, with MDM2 as a core target gene.
Answers are grounded in this paper and cite their sources.
Identifies potential YQSX targets in ITP; leaves open efficacy confirmation in randomized trials.
Yiqi Shexue formula (YQSX) is traditionally used to treat primary immune thrombocytopenia (ITP) in clinical practice of traditional Chinese medicine. However, its mechanisms of action and molecular targets for treatment of ITP are not clear. The active compounds of YQSX were collected and their targets were identified. ITP-related targets were obtained by analyzing the differential expressed genes between ITP patients and healthy individuals. Protein-protein interaction (PPI) data were then obtained and PPI networks of YQSX putative targets and ITP-related targets were visualized and merged to identify the candidate targets for YQSX against ITP. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis was carried out. The gene-pathway network was constructed to screen the key target genes. In total, 177 active compounds and 251 targets of YQSX were identified. Two hundred and thirty differential expressed genes with an P value 1 were identified between ITP patient and control groups. One hundred and eighty-three target genes associated with ITP were finally identified. The functional annotations of target genes were found to be related to transcription, cytosol, protein binding, and so on. Twenty-four pathways including cell cycle, estrogen signaling pathway, and MAPK signaling pathway were significantly enriched. MDM2 was the core gene and other several genes including TP53, MAPK1, CDKN1A, MYC, and DDX5 were the key gens in the gene-pathway network of YQSX for treatment of ITP. The results indicated that YQSX’s effects against ITP may relate to regulation of immunological function through the specific biological processes and the related pathways. This study demonstrates the application of network pharmacology in evaluating mechanisms of action and molecular targets of complex herbal formulations.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2019) studied Primary immune thrombocytopenia (ITP). Yiqi Shexue formula (YQSX) was evaluated on Identification of candidate targets and pathways for YQSX against ITP. Network pharmacology analysis identified 183 target genes and 24 pathways, including MDM2, TP53, and MAPK signaling, as key mechanisms for Yiqi Shexue formula in treating primary immune thrombocytopenia.
Synapse has enriched 10 related papers. Consider them for comparative context: